Hologic, Inc.
HOLXHologic owns critical tools in breast and cervical cancer screening, creating recurring revenue streams anchored in essential care.
Because essential healthcare can be durable, but only if growth and margins stabilize over time.
Business Model
Devices plus consumables
It sells diagnostic machines and then earns recurring revenue from tests, probes, and service contracts.
Economic Engine
High-margin recurring sales
Gross margins around 61 percent and strong cash conversion fund buybacks and reinvestment.
Long-Term Lens
Post-pandemic reset
The key question is whether core screening businesses can grow steadily after COVID testing faded.
On this page
Company Story
How do Hologic, Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A cash-rich women’s health franchise with real staying power, but future returns depend on reigniting steady growth after a post-pandemic reset.”
What does Hologic, Inc. actually do?
Hologic makes medical devices and diagnostic tests focused largely on women’s health.
- Mammography machines used to detect breast cancer
- Cervical cancer and sexually transmitted infection tests run in labs
- Surgical tools used in gynecology procedures
Why it matters
Essential healthcare niche
Cancer screening and core gynecology procedures are not optional, which supports long-term demand.
How does Hologic, Inc. make money?
It sells equipment upfront and then generates recurring revenue from consumables, tests, and service contracts.
- Initial sale of imaging or diagnostic systems to hospitals and labs
- Ongoing sale of single-use test kits and probes
- Service and maintenance agreements tied to installed machines
Economic clue
61 percent gross margin
High gross margins suggest pricing power and valuable recurring products tied to its installed base.
Why do long-term investors keep Hologic, Inc. on the radar?
It sits at the center of preventive care for millions of women, creating durable demand over decades.
- Aging populations increase cancer screening volumes
- Established installed base creates repeat test purchases
- Strong cash generation supports buybacks and investment
Investor takeaway
22.4 percent free cash flow margin
High cash margins give management flexibility to invest, acquire, or repurchase shares over long periods.
Based on company financial statements.
Benchmark Comparison
How has Hologic, Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$1,047
+4.7% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| HOLX | +4.7% | $1,047 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Hologic, Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to essential healthcare services with steady long-term demand
- A business that converts profits into real cash at a high rate
- Shareholder returns driven by buybacks rather than dividends
Be Careful If You Expect
- Fast and consistent double-digit revenue growth
- Rapid margin expansion from already healthy levels
- A meaningful dividend income stream
What To Watch Over Time
- Whether core revenue returns to steady mid single-digit annual growth
- If operating margin, now 17.4 percent, stabilizes or keeps contracting
- How effectively buybacks create per-share value over a decade
Key Metrics
Which metrics matter most for Hologic, Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
-7.6 percent per year over 5 years
-23.4 percent per year over 5 years
61.0 percent gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | -7.6 percent per year over 5 years | Shows that recent years included a revenue reset after pandemic-driven demand. |
| EPS Growth | -23.4 percent per year over 5 years | Highlights how dependent earnings were on temporary testing surges. |
| Margin Quality | 61.0 percent gross margin | Indicates strong pricing power and room to fund research and buybacks. |
Based on company financial statements.
Fundamentals
What do Hologic, Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
16.7% ROIC
61.0% gross margin
22.4% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 16.7% ROIC | The business is currently showing good capital efficiency. |
| Profitability | 61.0% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 22.4% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Hologic, Inc.?
Hologic, Inc. currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Hologic, Inc.?
Company-specific questions readers often ask about Hologic, Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Hologic makes medical imaging systems, diagnostic tests, and surgical tools focused largely on women’s health, especially breast and cervical cancer screening.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Cancer screening is a long-term necessity, and aging populations should steadily increase the number of mammograms and cervical cancer tests performed each year.
An installed base of diagnostic machines creates recurring consumable sales with 61 percent gross margins, supporting durable cash generation.
Free cash flow at 22.4 percent of revenue provides flexibility for buybacks, acquisitions, and research spending over decades.
Specialization in women’s health allows focused research and brand credibility in a niche that larger diversified competitors may not prioritize as deeply.
Bear case
What can break
Large diagnostics and imaging competitors could outspend Hologic in research and undercut pricing, pressuring its 17.4 percent operating margin over time.
Healthcare reimbursement changes could lower payments for screening tests, directly reducing demand or squeezing lab budgets.
Technological disruption, such as new non-invasive or at-home screening methods, could reduce reliance on Hologic’s installed systems.
The recent five-year average revenue decline of 7.6 percent per year may signal that pandemic gains masked a slower underlying growth profile.
Risk Radar
Key Risks
Where downside pressure can build.
Margin compression: Operating margin has fallen to 17.4 percent, and further declines of even 3 to 5 percentage points would significantly cut earnings power.
Earnings volatility: Earnings per share have declined 23.4 percent per year on average over five years, showing sensitivity to product mix shifts.
Capital allocation: 0.8 billion dollars in annual buybacks must create per-share value, or cash returns could be wasted.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $75.74
- Daily move
- -0.01%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.